HLA-Gs are a valid target in cancer therapy (Lin and Yan, 2015; Zhang et al., 2018); cytotoxicity studies show that HLA-Gs drastically inhibit lysis of human ovarian carcinoma cells, with subsequent immune evasion, and that lysis can be restored by the conformational anti-HLA-G mAb 87G (Tilburgs et al., 2015). This evidence concerns the gene HLA-G and ovarian carcinoma.